8-K Announcements
6Material company update
Apr 16, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Sep 22, 2025·SEC
Acurx Pharmaceuticals, Inc.(ACXP)Earnings, Financials & Key Ratios
ACXP•NASDAQ
Price updated Jun 19, 2026
AboutAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Show more
- Revenue$0
- EBITDA-$8M
- Net Income-$8M+43.5%
- EPS (Diluted)-5.32+69.8%
- ROE-270.8%+49.3%
ACXP Key Insights
Acurx Pharmaceuticals, Inc. (ACXP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Profits declining 11.6% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 6 (bottom 6%)
- ✗Shares diluted 76.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ACXP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACXP Price & Volume
Acurx Pharmaceuticals, Inc. (ACXP) stock price & volume — 10-year historical chart
Loading chart...
ACXP Growth Metrics
Acurx Pharmaceuticals, Inc. (ACXP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM36.85%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM65.1%
Return on Capital
10 Years-332.16%
5 Years-268.81%
3 Years-350.81%
Last Year-275.06%
ACXP Recent Earnings
Acurx Pharmaceuticals, Inc. (ACXP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.62-5.1%
$0.59
Rev
—
—
Q2 2026
Mar 13, 2026Metric
Actual
Est
EPS
$0.31+69.3%
$1.01
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$1.23+23.6%
$1.61
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$1.89+5.5%
$2.00
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.62vs $0.59-5.1% | — |
| Q2 2026 | Mar 13, 2026 | $0.31vs $1.01+69.3% | — |
| Q4 2025 | Nov 12, 2025 | $1.23vs $1.61+23.6% | — |
| Q3 2025 | Aug 11, 2025 | $1.89vs $2.00+5.5% | — |
Based on last 12 quarters of dataView full earnings history →
ACXP Peer Comparison
Acurx Pharmaceuticals, Inc. (ACXP) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ACIU | 244.26M | 2.40 | -2.74 | -86.92% | -19.69% | -101.6% | 0.10 | |
 LPSN | 24.47M | 2.01 | -0.16 | -22% | -26.24% | |||
 NAOV | 512.71K | 1.90 | -0.14 | -0.2% | -8.95% | -52.57% | 0.00 | |
 PHAT | 864.2M | 10.88 | -3.59 | 216.93% | -61.95% | |||
 CLDX | 2.16B | 32.43 | -8.32 | -78.63% | -345.96% | -50.72% | 0.00 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 MTNB | 3.56M | 0.60 | -0.12 | -100% | -270.65% | 0.38 |
Compare ACXP vs Peers
Acurx Pharmaceuticals, Inc. (ACXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACXP Income Statement
Acurx Pharmaceuticals, Inc. (ACXP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | - |
Operating Expenses | 5.93M | 4.6M | 12.81M | 12.09M | 14.58M | 14.1M | 8.09M | 7.63M |
OpEx % of Revenue | - | - | - | - | - | - | - | - |
Selling, General & Admin | 2.42M | 2.4M | 10.78M | 7.34M | 8.53M | 8.7M | 6.26B | 7.63B |
SG&A % of Revenue | - | - | - | - | - | - | - | - |
Research & Development | 3.51M | 2.2M | 2.03M | 4.75M | 6.04M | 5.4M | 1.83B | 1.83B |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -8.08B | -2M |
Operating Income | -5.93M▲ 0% | -4.6M▲ 22.4% | -12.81M▼ 178.6% | -12.09M▲ 5.6% | -14.58M▼ 20.5% | -14.1M▲ 3.3% | -8.09M▲ 42.6% | -7.63M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 22.44% | -178.57% | 5.63% | -20.55% | 3.26% | 42.62% | - |
EBITDA | 0 | 0 | -12.81M | -12.09M | -14.58M | 0 | -8.09M | -7.63M |
EBITDA Margin % | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | - | 5.63% | -20.55% | 100% | - | -85.11% |
D&A (Non-Cash Add-back) | 5.93M | 4.6M | 0 | 0 | 0 | 14.1M | 0 | 0 |
EBIT | -5.93M | -4.6M | -12.81M | -12.09M | -14.58M | -14.1M | -8.09M | -7.63M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 125.44K | 133.16K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 125.44K | 133.16K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 0 | 0 | 66.5K | 0 | 0 | 0 | 125.44K | 133.16K |
Pretax Income | -5.93M▲ 0% | -4.6M▲ 22.4% | -12.75M▼ 177.1% | -12.09M▲ 5.1% | -14.58M▼ 20.5% | -14.1M▲ 3.3% | -7.97M▲ 43.5% | -7.5M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -5.93M▲ 0% | -4.6M▲ 22.4% | -12.75M▼ 177.1% | -12.09M▲ 5.1% | -14.58M▼ 20.5% | -14.1M▲ 3.3% | -7.97M▲ 43.5% | -7.5M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - |
Net Income Growth % | - | 22.44% | -177.12% | 5.14% | -20.55% | 3.26% | 43.51% | 36.85% |
Net Income (Continuing) | -5.93M | -4.6M | -12.75M | -12.09M | -14.58M | -14.1M | -7.97M | -7.5M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -12.00▲ 0% | -9.28▲ 22.7% | -24.96▼ 169.0% | -22.36▲ 10.4% | -23.01▼ 2.9% | -17.59▲ 23.6% | -5.32▲ 69.8% | -5.00▲ 0% |
EPS Growth % | - | 22.67% | -168.97% | 10.42% | -2.91% | 23.55% | 69.76% | 65.1% |
EPS (Basic) | -12.00 | -9.28 | -24.96 | -22.36 | -23.01 | -17.59 | -5.32 | - |
Diluted Shares Outstanding | 477.05K | 495.8K | 510.8K | 540.8K | 633.6K | 851.55K | 1.5M | 1.5M |
Basic Shares Outstanding | 375.1K | 495.8K | 510.8K | 540.8K | 633.6K | 851.55K | 1.5M | 1.5M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ACXP Balance Sheet
Acurx Pharmaceuticals, Inc. (ACXP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.53M | 3.22M | 13.25M | 9.38M | 7.71M | 3.86M | 7.69M | 9.54M |
Cash & Short-Term Investments | 2.48M | 3.18M | 12.96M | 9.11M | 7.47M | 3.71M | 7.56B | 9.25M |
Cash Only | 2.48M | 3.18M | 12.96M | 9.11M | 7.47M | 3.71M | 7.56B | 9.25M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 129.16K | 51.13K | 48.42K | 56.31K |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | -7.55B | 0 |
Total Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 2.53M▲ 0% | 3.22M▲ 27.4% | 13.25M▲ 311.1% | 9.38M▼ 29.3% | 7.71M▼ 17.8% | 3.86M▼ 50.0% | 7.69M▲ 99.3% | 9.54M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 27.36% | 311.11% | -29.25% | -17.78% | -49.96% | 99.32% | 193.46% |
Total Current Liabilities | 1.71M | 472.56K | 843.91K | 2.06M | 3.04M | 3.24M | 2.42M | 2.53M |
Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 16.63K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.31M | 317.07K | 508.34K | 542.89K | 716.31K | 537.63K | 2.41M | 2.5M |
Current Ratio | 1.48x | 6.82x | 15.71x | 4.55x | 2.53x | 1.19x | 3.18x | 3.78x |
Quick Ratio | 1.48x | 6.82x | 15.71x | 4.55x | 2.53x | 1.19x | 3.18x | 3.78x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 49.88K | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 49.88K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.71M | 522.43K | 843.91K | 2.06M | 3.04M | 3.24M | 2.42M | 2.53M |
Total Debt | 0 | 66.5K | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | -2.48M | -3.11M | -12.96M | -9.11M | -7.47M | -3.71M | -7.56B | -9.25M |
Debt / Equity | - | 0.02x | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 1.21x |
Interest Coverage | - | - | - | - | - | - | - | - |
Total Equity | 819.85K▲ 0% | 2.7M▲ 229.5% | 12.41M▲ 359.4% | 7.32M▼ 41.1% | 4.67M▼ 36.2% | 615.12K▼ 86.8% | 5.27M▲ 756.5% | 7.01M▲ 0% |
Equity Growth % | - | 229.52% | 359.37% | -41.06% | -36.2% | -86.82% | 756.51% | 1000.51% |
Book Value per Share | 1.72 | 5.45 | 24.30 | 13.53 | 7.37 | 0.72 | 3.51 | 4.68 |
Total Shareholders' Equity | 819.85K | 2.7M | 12.41M | 7.32M | 4.67M | 615.12K | 5.27M | 7.01M |
Common Stock | 10.02M | 16.5M | 10.22K | 11.63K | 14.47K | 17.03K | 2.35K | 3.39K |
Retained Earnings | -9.2M | -13.8M | -26.55M | -38.64M | -53.22M | -67.32M | -75.29M | -76.97M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -9.2M | -13.8M | -26.55M | -38.64M | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACXP Cash Flow Statement
Acurx Pharmaceuticals, Inc. (ACXP) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.99M | -3.35M | -5.01M | -7.54M | -9.8M | -10.38M | -6.79B | -6.14M |
Operating CF Margin % | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | 15.9% | -49.59% | -50.43% | -29.95% | -5.94% | -65271.28% | 134.85% |
Net Income | -5.93M | -4.6M | -12.75M | -12.09M | -14.58M | -14.1M | -7.97B | -7.5M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 900.43K | 1.27M | 6.74M | 3.3M | 3.77M | 3.44M | 1.25B | 1.13M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 781.7K | 850.26K | 0 | 0 | 0 | -68.25M | 319.29K |
Working Capital Changes | 1.05M | -801.17K | 141.28K | 1.25M | 1.01M | 284.09K | -390.96K | -90.82K |
Change in Receivables | 0 | 0 | 0 | 0 | -129.16K | 78.03K | 2.71K | -56.31K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 4.46M | 4.04M | 14.8M | 3.7M | 8.16M | 6.62M | 10.64B | 10.75M |
Debt Issued (Net) | 0 | 66.5K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 4.46M | 3.98M | 14.8M | 3.7M | 5.94M | 6.41M | 10.64M | 8.28M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 13 | 2.22M | 210.2K | 10.63B | 2.48M |
Net Change in Cash | 470.17K▲ 0% | 692.09K▲ 47.2% | 9.78M▲ 1313.6% | -3.85M▼ 139.3% | -1.64M▲ 57.4% | -3.77M▼ 130.1% | 3.85B▲ 102274.2% | 4.61M▲ 0% |
Free Cash Flow | -3.99M▲ 0% | -3.35M▲ 15.9% | -5.01M▼ 49.6% | -7.54M▼ 50.4% | -9.8M▼ 29.9% | -10.38M▼ 5.9% | -6.79B▼ 65271.3% | -6.14M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - |
FCF Growth % | - | 15.9% | -49.59% | -50.43% | -29.95% | -5.94% | -65271.28% | 34.45% |
FCF per Share | -8.35 | -6.76 | -9.82 | -13.95 | -15.47 | -12.19 | -4528.21 | -4.10 |
FCF Conversion (FCF/Net Income) | 0.67x | 0.73x | 0.39x | 0.62x | 0.67x | 0.74x | 852.04x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACXP Key Ratios
Acurx Pharmaceuticals, Inc. (ACXP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -261.26% | -168.71% | -122.61% | -243.33% | -534.03% | -270.8% | -153.93% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | 0.3% |
Debt / Equity | 0.02x | - | - | - | - | - | 0.00x |
FCF Conversion | 0.73x | 0.39x | 0.62x | 0.67x | 0.74x | 852.04x | 0.82x |
Related:ACXP Dividend History·ACXP Revenue History·ACXP Price History·ACXP P/E History·ACXP Financial Ratios·ACXP Institutional Holders
ACXP SEC Filings & Documents
Acurx Pharmaceuticals, Inc. (ACXP) SEC filings — annual & quarterly reports (10-K, 10-Q)
ACXP Frequently Asked Questions
Acurx Pharmaceuticals, Inc. (ACXP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Acurx Pharmaceuticals, Inc. (ACXP) grew revenue by 0.0% over the past year. Growth has been modest.
Acurx Pharmaceuticals, Inc. (ACXP) reported a net loss of $7.5M for fiscal year 2025.
Dividend & Returns
Acurx Pharmaceuticals, Inc. (ACXP) has a return on equity (ROE) of -270.8%. Negative ROE indicates the company is unprofitable.
Acurx Pharmaceuticals, Inc. (ACXP) had negative free cash flow of $6.1M in fiscal year 2025, likely due to heavy capital investments.